PublicationsDiatech Admin2018-12-12T10:54:12+01:00

Publications

Leader in the development, production and
commercialisation of pharmacogenetics tests
for cancer precision medicine.

2711, 2016

Adriana Romiti et al., The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer. Anti-Cancer Drugs

2511, 2016

Laura Capelli et al., No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC). Scientific Reports

1211, 2016

Greta Alì et al., Small cell lung cancer transformation and the T790M mutation: A case report of two acquired mechanisms of TKI resistance detected in a tumor rebiopsy and plasma sample of EGFR-mutant lung adenocarcinoma. Oncology Letters

1211, 2016

Caterina Marchiò et al., Liquoral liquid biopsy in neoplastic meningitis enables molecular diagnosis and mutation tracking: a proof of concept. Neuro-Oncology

811, 2016

Federico Pessina et al., Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in an observational study. Journal of Neuro-Oncology

811, 2016

Harriet Johansson et al., Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. Breast Cancer Research

2610, 2016

Annemarie Boleij et al., RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres. BMC Cancer

1110, 2016

Giovanna De Maglio et al., Management optimization of non small cell lung cancer (NSCLC) specimens. A single institution experience with a multiplexed mass spectrometry approach. Annals of Oncology

1110, 2016

Annarita Destro et al., The impact of mass spectrometry multigenic platform on the management of metastatic colorectal patients. Annals of Oncology

1110, 2016

Elisa Chiadini et al., Frequency of driver mutations in EGFR wt NSCLC using mass spectrometry: Experience of Area Vasta Romagna. Annals of Oncology

110, 2016

Véronique Quilien et al., P06.13?A low baseline blood neutrophil count and a high percentage of Treg among leucocytes are associated with an increased overall survival of recurrent high-grade glioma patients treated with Bevacizumab. Neuro Oncology

110, 2016

Marie Duhamel et al., P06.11 Classification of high-grade glioma using Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry imaging (MALDI MSI): interim results of the GLIOMIC study. Neuro Oncology

Previous 222324 Next